Eun Yang
Stock Analyst at Jefferies
(0.45)
# 4,157
Out of 5,049 analysts
36
Total ratings
31.58%
Success rate
-26.79%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RIGL Rigel Pharmaceuticals | Upgrades: Buy | $23 → $42 | $36.12 | +16.28% | 1 | Nov 5, 2025 | |
| ATXS Astria Therapeutics | Downgrades: Hold | $30 → $13 | $12.42 | +4.71% | 3 | Oct 14, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $454.00 | -4.85% | 8 | Sep 23, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $3.92 | +104.08% | 2 | May 14, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $7 → $1.5 | $0.64 | +134.82% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $62.73 | -47.39% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $1.30 | +2,053.85% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $18.30 | +47.54% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $2.40 | +191.67% | 1 | Feb 10, 2023 | |
| CVAC CureVac | Upgrades: Buy | n/a | $5.25 | - | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $4.18 | +498.80% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $105,000 → $15,000 | $3.64 | +411,987.91% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $4.04 | +518.81% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $22.83 | +53.34% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $315.59 | -30.29% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $156.74 | +97.78% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $123.40 | -35.17% | 3 | Jul 11, 2017 |
Rigel Pharmaceuticals
Nov 5, 2025
Upgrades: Buy
Price Target: $23 → $42
Current: $36.12
Upside: +16.28%
Astria Therapeutics
Oct 14, 2025
Downgrades: Hold
Price Target: $30 → $13
Current: $12.42
Upside: +4.71%
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $454.00
Upside: -4.85%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $3.92
Upside: +104.08%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $7 → $1.5
Current: $0.64
Upside: +134.82%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $62.73
Upside: -47.39%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $1.30
Upside: +2,053.85%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $18.30
Upside: +47.54%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $2.40
Upside: +191.67%
CureVac
Jan 9, 2023
Upgrades: Buy
Price Target: n/a
Current: $5.25
Upside: -
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $4.18
Upside: +498.80%
Sep 22, 2022
Maintains: Buy
Price Target: $105,000 → $15,000
Current: $3.64
Upside: +411,987.91%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $4.04
Upside: +518.81%
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $22.83
Upside: +53.34%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $315.59
Upside: -30.29%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $156.74
Upside: +97.78%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $123.40
Upside: -35.17%